Page 236 - 2021_06-Haematologica-web

Letters to the Editor
used selinexor to-date. The aggressive lymphoma field needs treatment selection factors now more than another marker of overall prognosis. We recommend that CRM1 staining and intensity grading be included in ongoing and future clinical trials to learn if CRM1 intensity predicts selinexor response.
Jithma P. Abeykoon,1* Paul J. Hampel,1* Rebecca L. King,2*
Adam J. Wood,2* Melissa C. Larson,3* Kevin E.
Nowakowski,1 Saurabh S. Zanwar,1 Surendra Dasari,3
Gordon J. Ruan,1 Aishwarya Ravindran,2 Linda E. Wellik,1
Jonas Paludo,1 Brian K. Link,4 James R. Cerhan,3 Stephen M.
Ansell,1 Grzegorz S. Nowakowski,1 Carrie A Thompson,1
Matthew J. Maurer,3 Kerstin Wenzl,1 Anne J. Novak,1
11 Xiaosheng Wu, Thomas M. Habermann
and Thomas E. Witzig1
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; 2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN and 4Division of Hematology, University of Iowa, Iowa City, IA, USA
*JPA, PJH, RLK, AJW and MCL contributed equally as co-first authors.
Correspondence:
THOMAS E. WITZIG - witzig.thomas@mayo.edu
doi:10.3324/haematol.2020.278277
Received: December 30, 2020.
Accepted: February 23, 2021.
Pre-published: March 4, 2021.
Disclosures: TEW served on an advisory board meeting in 2018 and 2020 for Karyopharm Pharmaceuticals-personally compensated and serves on other advisory boards but none have any bearing
on the subject of this manuscript; MM serves on the advisory board of MorphoSys, Kite Pharama, Pfizer, and receives research funding
(to Mayo Clinic) from Celgene, NanoString Technologies, Genetech and Morphosys; SMA receives research funding (to Mayo Clinic) from Bristol Myers Squibb, Seattle Genetics, Takeda, Regeneron, ADC Therapeutics, Affimed, Trillium, and AI Therapeutics; BKL serves as a consultant for Genentech and MEI inc. The rest of the authors declare no competing financial interests.
Contributions: JPA, PJH, RLK, AJW, XW, TMH and TEW conceptually designed the study; JPA, PJH, RK, AJW, MCL, KEN, SSZ, SD, GJR, JP, BKL, JRC, SMA, GSN, CAT, KW, AJN, MJM, AR acquired analyzed and interpreted data; RLK, AJW were the expert pathologists; LEW performed IHC staining.
Funding: this work was funded by ASCO Conquer Cancer Young Investigator Award, supported by The Hearst Foundation. Any opin- ions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology®, Conquer Cancer®, or The Hearst Foundation. This research was also supported in part by the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274), the Mayo
Clinic and the Predolin Foundation Biobank.
References
1. Taylor J, Sendino M, Gorelick AN, et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 2019; 9(10):1452-1467.
2. Yue L, Sun ZN, Yao YS, et al. CRM1, a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis. Oncol Lett. 2018;15(5):7515-7522.
3. Abeykoon JP, Paludo J, Nowakowski KE, et al. The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. Blood Cancer J. 2019;9(3):24.
4. Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and tar- geting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166-4174.
5. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522.
6. Inoue H, Kauffman M, Shacham S, et al. CRM1 blockade by selec- tive inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013;189(6):2317-2326.
7. Luo B, Huang L, Gu Y, et al. Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. Int J Clin Exp Pathol. 2018;11(12):5547-5560.
8. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus ritux- imab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
9. Deng M, Zhang M, Xu-Monette ZY, et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020;13(1):148.
10. Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066-1073.
11. Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol. 2012;3(2):137-151.
12. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 2005;46(3):258-268.
13. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of dif- fuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
14. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.e15.
15. Miloudi H, Bohers É, Guillonneau F, et al. XPO1(E571K) Mutation modifies exportin 1 localisation and interactome in B-cell lymphoma. Cancers (Basel). 2020;12(10):2829.
2264
haematologica | 2021; 106(8)